TCL Archive Phase III Trial of Talimogene Laherparepvec Meets Response Rate Primary Endpoint March 29, 2013
TCL Archive NCI Expects 200 CCP applications; Grand Rapids Workshop To Offer Last Chance to Ask Questions September 24, 1982